Asthma Therapeutics Market by Product, Drug Class, Route of administration

List of Tables

[183 Pages Report] The Asthma Therapeutics Market size was estimated at USD 22.39 billion in 2022 and expected to reach USD 24.70 billion in 2023, at a CAGR 10.59% to reach USD 50.10 billion by 2030.

Global Asthma Therapeutics Market

KEY MARKET STATISTICS
Base Year [2022]	USD 22.39 billion
Estimated Year [2023]	USD 24.70 billion
Forecast Year [2030]	USD 50.10 billion
CAGR (%)	10.59%

The asthma therapeutics market encompasses all activities related to the research, development, production, and distribution of medications and treatments designed to manage and alleviate the symptoms of asthma, a chronic respiratory disorder. This market serves a diverse population of patients across age groups who require either maintenance therapy or acute care for asthmatic episodes. The market scope includes various therapeutic products such as anti-inflammatory drugs, bronchodilators, combination therapies, biologics, and delivery devices such as inhalers and nebulizers. The primary applications within the asthma therapeutics market include long-term control medicines, which aim to maintain a stable condition, and quick-relief treatments for sudden symptoms. End-users of these products typically entail individuals diagnosed with asthma, healthcare professionals like pulmonologists, and healthcare settings, including hospitals, clinics, and homecare environments. The scope extends to support services like patient education and training on the proper use of asthma management devices. The need for asthma therapeutics is increasing due to growing incidences of asthma and other respiratory diseases, recent improvements in allergy detection and diagnostic technologies, and extensive demand for monoclonal antibodies. However, the asthma therapeutics market faces certain challenges, including limitations and side effects of asthma therapeutic devices, high costs associated with advanced treatments, and limited therapeutic reach in remote and rural areas. On the other hand, several opportunities are emerging within the asthma therapeutics market, including the development of combination therapeutics for the treatment and extensive research and development (R&D) efforts for asthma treatment. There is also an increasing trend towards digital health solutions, such as smart inhalers that can track usage and remind patients about doses, opening opportunities for tech companies and pharmaceutical partnerships.

Regional Insights

In the United States, the asthma therapeutics market is driven by a high prevalence of asthma alongside strong healthcare infrastructure. Patent expirations, novel biologics, and personalized medicine drive research and innovation in the region. Various organizations in the region continue to find a cure for and control asthma, food allergies, nasal allergies, and other allergic diseases. South America shows a growing need for asthma therapeutics, largely due to increasing awareness of respiratory diseases and improving healthcare facilities. Europe represents a substantial market for asthma therapeutics, supported by high awareness levels, established healthcare systems, and favorable reimbursement policies. The presence of several key market players and a strong emphasis on research and development activities are notable factors. Western European countries, including Germany, France, Switzerland, the United Kingdom, France, and Italy, hold a major market share, while Eastern European countries exhibit potential for growth due to improving healthcare infrastructure and rising asthma prevalence. The market in the Middle East is advancing with the development of healthcare infrastructure and increasing private sector investment. In contrast, Africa faces challenges such as limited healthcare services, low awareness, and inadequate access to treatment, which hinder market growth. However, certain countries, including South Africa, are making strides in asthma care, which can positively influence regional market development. In APAC, China's asthma therapeutic market is developing rapidly due to the growing middle class and enhanced healthcare reforms. In Japan, patients have access to several state-of-the-art treatments, reflecting the country's advanced healthcare system and high patient awareness. Japan's pharmaceutical sector is highly innovative, with a robust pipeline of new drugs and consistent investment in R&D. India's asthma treatment market is characterized by a need for affordable medications and increased education on asthma management. The high population, coupled with pollution issues, contributes to a growing prevalence of asthma. Government programs and non-profit initiatives aim to enhance asthma care accessibility and affordability throughout the subcontinent.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Asthma Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Asthma Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Asthma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Chiesi Farmaceutici S.p.A., Cipla Limited, F. Hoffmann-La Roche Ltd, Genentech, Inc., GlaxoSmithKline PLC, Kare Medical and Analytical Devices Ltd. Co., Koninklijke Philips N.V., Lupin Limited, Medtronic PLC, Merck & Co, Inc., Merxin Ltd., Novartis AG, Parekhplast India Limited, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Shenzhen Aeon Technology Co., Ltd., Softhale NV by invoX Pharma Limited, Sun Pharmaceutical Industries Limited, Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Trudell Medical Limited, Viatris Inc., and Wellinks, Inc..

Market Segmentation & Coverage

This research report categorizes the Asthma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Inhalers
  - Dry Powder Inhalers
  - Metered-Dose Inhalers
  - Soft Mist Inhalers
- Nebulizers
Drug Class
- Anti-Inflammatory
- Bronchodilators
- Combination Therapy
Route of administration
- Inhaled
- Oral
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Asthma Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Asthma Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Asthma Therapeutics Market?

4. What is the market share of the leading vendors in the Asthma Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Asthma Therapeutics Market?

Product Code: MRR-AB49FC1AB824

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Asthma Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing Incidences of Asthma and Other Respiratory Diseases
  - 5.1.1.2. Recent Improvements in Allergy Detection and Diagnostic Technologies
  - 5.1.1.3. Extensive Demand for Monoclonal Antibodies
- 5.1.2. Restraints
  - 5.1.2.1. Limitation and Side Effects of Asthma Therapeutic Devices
- 5.1.3. Opportunities
  - 5.1.3.1. Development of Combination Therapeutics for The Treatment
  - 5.1.3.2. Extensive Research and Development (R&D) Efforts for Asthma Treatment
- 5.1.4. Challenges
  - 5.1.4.1. Limited Therapeutics Reach in Remote & Rural Areas
5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising demand for metered dose inhalers for the treatment of asthma
- 5.2.2. Drug Class: Growing usage of anti-Inflammatory drugs in asthma therapeutics
- 5.2.3. Route of administration: Expanding adoption of inhaled asthma medication for fast relief
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter's Five Forces Analysis
- 5.7.1. Threat of New Entrants
- 5.7.2. Threat of Substitutes
- 5.7.3. Bargaining Power of Customers
- 5.7.4. Bargaining Power of Suppliers
- 5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization

6. Asthma Therapeutics Market, by Product

6.1. Introduction
6.2. Inhalers
- 6.3.1. Dry Powder Inhalers
- 6.3.2. Metered-Dose Inhalers
- 6.3.3. Soft Mist Inhalers
6.3. Nebulizers

7. Asthma Therapeutics Market, by Drug Class

7.1. Introduction
7.2. Anti-Inflammatory
7.3. Bronchodilators
7.4. Combination Therapy

8. Asthma Therapeutics Market, by Route of administration

8.1. Introduction
8.2. Inhaled
8.3. Oral

9. Americas Asthma Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Asthma Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Asthma Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. Merger & Acquisition
  - 12.3.1.1. GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition
- 12.3.2. Agreement, Collaboration, & Partnership
  - 12.3.2.1. Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
- 12.3.3. New Product Launch & Enhancement
  - 12.3.3.1. Lupin Launches Luforbec® 100/6 for Adult Asthma and COPD Treatment

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. Amgen Inc.
- 13.1.3. AstraZeneca PLC
- 13.1.4. Biogen Inc.
- 13.1.5. Boehringer Ingelheim GmbH
- 13.1.6. Boston Scientific Corporation
- 13.1.7. Chiesi Farmaceutici S.p.A.
- 13.1.8. Cipla Limited
- 13.1.9. F. Hoffmann-La Roche Ltd
- 13.1.10. Genentech, Inc.
- 13.1.11. GlaxoSmithKline PLC
- 13.1.12. Kare Medical and Analytical Devices Ltd. Co.
- 13.1.13. Koninklijke Philips N.V.
- 13.1.14. Lupin Limited
- 13.1.15. Medtronic PLC
- 13.1.16. Merck & Co, Inc.
- 13.1.17. Merxin Ltd.
- 13.1.18. Novartis AG
- 13.1.19. Parekhplast India Limited
- 13.1.20. Pfizer Inc.
- 13.1.21. Regeneron Pharmaceuticals, Inc.
- 13.1.22. Sanofi S.A.
- 13.1.23. Shenzhen Aeon Technology Co., Ltd.
- 13.1.24. Softhale NV by invoX Pharma Limited
- 13.1.25. Sun Pharmaceutical Industries Limited
- 13.1.26. Sunovion Pharmaceuticals, Inc.
- 13.1.27. Takeda Pharmaceutical Company
- 13.1.28. Teva Pharmaceutical Industries Ltd.
- 13.1.29. Trudell Medical Limited
- 13.1.30. Viatris Inc.
- 13.1.31. Wellinks, Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing